Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 24, 2025
Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025
GlobeNewswire
·
April 24, 2025
Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research …
BioNTech präsentiert auf der AACR-Jahrestagung 2025 klinische und präklinische Daten zu mRNA- und Immunonkologie-Fokus-Programmen
GlobeNewswire
·
April 24, 2025
MAINZ, Deutschland, 24. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer Research („AACR“), die vom 25. bis 30. April 2025 in Chicago, …
Best Oral Steroid for Strength in 2025: Top Steroids for Bodybuilding, Cutting, Muscle Growth & Raw Power (By Crazy Bulk)
GlobeNewswire
·
April 24, 2025
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- The best oral steroids aren’t just about size — they’re about performance, power, and pushing your body beyond its current limits. Whether you're a powerlifter aiming for new PRs, a CrossFit athlete chasing …
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
GlobeNewswire
·
April 24, 2025
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9), a clinical-stage biotechnology company advancing a …
Orion Oyj:n nimitysvaliokunnan kokoonpano
GlobeNewswire
·
April 24, 2025
ORION OYJ PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT 24.4.2025 KLO 11.00 Orion Oyj:n nimitysvaliokunnan kokoonpano Orion Oyj:n hallitus on nimittänyt yhtiön nimitysvaliokunnan jäseniksi seuraavat henkilöt: …
ProDentim Reviews (Ingredients, Complaints & Side Effects) 2025 – Honest User Feedback on Dental Benefits and Real Results
GlobeNewswire
·
April 24, 2025
TALLMADGE, Ohio, April 24, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of dental care, ProDentim has quickly gained attention as a game-changing supplement, offering a fresh take on how we support oral health. As buzz continues to grow, so does …
iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial
GlobeNewswire
·
April 24, 2025
For immediate release iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial Five-year safety profile including corneal health confirmed and 38% IOP reduction sustained Over 5000 patients …
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
GlobeNewswire
·
April 24, 2025
Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations underway to initiate Phase 2b study Gosselies, Belgium, 24 …
Bioxodes annonce des données intermédiaires positives pour son essai de phase 2a portant sur BIOX-101 dans le traitement de l’AVC hémorragique
GlobeNewswire
·
April 24, 2025
Le critère d’évaluation principal a été atteint, aucun événement indésirable grave associé au médicament n’a été rapporté L’évolution du volume de l’hématome et de l’œdème est favorable Le recrutement des patients a été arrêté plus tôt que prévu en raison …
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
GlobeNewswire
·
April 24, 2025
Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options Patients treated with elafibranor versus placebo showed …
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
GlobeNewswire
·
April 24, 2025
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER1 and business EPS2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO Dupixent sales were €3.5 billion, up 20. …
ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX Best Market
GlobeNewswire
·
April 24, 2025
Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch BNY will be ADR depositary bank Ticker symbol for US investors is ONWRY EINDHOVEN, the Netherlands, April 24, 2025 (GLOBE NEWSWIRE) -- …
Starke Verkäufe von Cresemba® (Isavuconazol) in Japan lösen zweite Umsatzmeilensteinzahlung von Asahi Kasei Pharma an Basilea aus
GlobeNewswire
·
April 24, 2025
Allschwil, 24. April 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, …
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
GlobeNewswire
·
April 24, 2025
Allschwil, Switzerland, April 24, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of …
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
GlobeNewswire
·
April 24, 2025
Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPREME-2 trial investigates the efficacy and safety of …
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
GlobeNewswire
·
April 24, 2025
Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will …
Merus gibt Annahme von Abstract zur Präsentation auf der ASCO®-Jahrestagung 2025 bekannt
GlobeNewswire
·
April 24, 2025
- Vorläufige klinische Daten zu Petosemtamab in Kombination mit Pembrolizumab bei 1L PD-L1+ r/m HNSCC für Posterpräsentation ausgewählt - Telefonkonferenz am Donnerstag, 22. Mai, um 17:30 Uhr Eastern Time zur Besprechung des vollständigen ASCO®-Datensatzes …
Merus annonce l’acceptation de son résumé pour présentation au congrès annuel 2025 de l’ASCO®
GlobeNewswire
·
April 24, 2025
- Le pétosemtamab en association avec le pembrolizumab en traitement de première intention d'un CETC r/m PD-L1+ : premières données cliniques provisoires sélectionnées pour une présentation sous forme d’affiche - Conférence téléphonique le jeudi 22 mai à …
Test Your Poison Launches Drug Testing Kits to Improve Public Safety and Address Drug Contamination Risks at Festivals and Nightclubs
GlobeNewswire
·
April 24, 2025
Test Your Poison Logo LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Test Your Poison, a leader in harm reduction since 2020, has introduced a new line of drug testing kits designed to help individuals identify harmful contaminants in substances like MDMA …
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
GlobeNewswire
·
April 24, 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including …